

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.


VISEN Pharmaceuticals
维昇药业
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2561)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 26 JUNE 2026; AND
(2) APPOINTMENTS OF NON-EXECUTIVE DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of VISEN Pharmaceuticals (the “**Company**”) is pleased to announce the poll results in respect of the resolutions (the “**Resolutions**”) proposed at the annual general meeting (the “**AGM**”) of the Company held on June 26, 2026. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the circular of the Company dated April 27, 2026 (the “**Circular**”) and the supplemental circular of the Company dated June 17, 2026 (the “**Supplemental Circular**”).

(1) POLL RESULTS OF THE AGM

The poll results in respect of the Resolutions were as follows:

Ordinary Resolutions		Number of Votes (%) ^{(Note (a))}	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2025.	84,786,110 (100%)	0 (0%)
2(a).	To re-elect Mr. LU An-Bang as an executive Director of the Company;	84,775,410 (99.987380%)	10,700 (0.012620%)
2(b).	To re-elect Dr. YAO Zhengbin (Bing) as an independent non-executive Director of the Company;	84,786,110 (100%)	0 (0%)
2(c).	To re-elect Mr. ZHANG Qing as an independent non-executive director of the Company;	84,786,110 (100%)	0 (0%)
2(d).	To authorise the board of directors of the Company to fix the respective Directors’ remuneration;	84,786,110 (100%)	0 (0%)
2(e).	To appoint Mr. Roy Paul Khoury as a non-executive director of the Company;	79,299,937 (99.986509%)	10,700 (0.013491%)
2(f).	To appoint Ms. Sherrie Lynn Glass as a non-executive director of the Company; and	79,299,937 (99.986509%)	10,700 (0.013491%)
2(g).	To appoint Mr. Michael J. Chang as a non-executive director of the Company.	79,299,937 (99.986509%)	10,700 (0.013491%)

Ordinary Resolutions		Number of Votes (%) ^{(Note (a))}	
		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of Directors to fix their remuneration.	84,786,110 (100%)	0 (0%)
4.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	84,786,110 (100%)	0 (0%)
5.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	84,786,110 (100%)	0 (0%)
6.	To extend, conditional upon the passing of resolutions no. 4 and 5, the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	84,786,110 (100%)	0 (0%)

Notes:

- (a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.
- (b) As a majority of the votes were cast in favour of each of the Resolutions, all the ordinary resolutions at the AGM were duly passed.
- (c) As at the date of the AGM, the total number of shares of the Company in issue was 113,926,864 shares, which included 169,200 treasury shares (including any treasury shares held or deposited in the Central Clearing and Settlement System) and no shares that the Company had repurchased but not yet cancelled.
- (d) The total number of shares of the Company entitling the holder to attend and vote on the Resolutions was 113,757,664 shares. Tricor Trust (Hong Kong) Limited, being the trustee holding 2,958,000 unvested RSUs granted under the Equity Incentive Plan; and Tricor Equity Trustee Limited being the trustee holding 1,500,000 Shares underlying RSUs granted to Mr. Lu under the Equity Incentive Plan, were required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules. The 169,200 treasury shares were excluded from the total number of Shares entitling the holder to attend and vote on the Resolutions. Shareholders and authorised proxies holding an aggregate of 84,786,110 shares voted at the AGM, while the shareholders and authorised proxies holding an aggregate of 79,310,637 shares voted on Resolutions 2(e) to 2(g) proposed at the AGM.
- (e) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").
- (f) No shareholder of the Company was required under the Listing Rules to abstain from voting at the AGM.
- (g) None of the shareholders of the Company have stated their intention in the Circular and the Supplemental Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
- (h) The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (i) All Directors attended the AGM in person or by electronic means.

(2) APPOINTMENTS OF NON-EXECUTIVE DIRECTORS

Following the approval by the Shareholders at the AGM, the appointments of Mr. Roy Paul Khoury (“**Mr. Khoury**”), Ms. Sherrie Lynn Glass (“**Ms. Glass**”) and Mr. Michael J. Chang (“**Mr. Chang**”) as non-executive Directors have become effective from June 26, 2026. The biographical details of Mr. Khoury, Ms. Glass and Mr. Chang and other information disclosed in accordance with Rule 13.51(2) of the Listing Rules are set out in the Supplemental Circular. As of the date of this announcement, there was no change in that information.

The Board would like to take this opportunity to express its warmest welcome to Mr. Khoury, Ms. Glass and Mr. Chang on their appointment as non-executive Directors of the Company.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, 26 June 2026

As at the date of this announcement, the board of directors comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan, Mr. CAO Yibo, Mr. Roy Paul KHOURY, Ms. Sherrie Lynn GLASS and Mr. Michael J. CHANG as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.